What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

Anand P. Jillella, Celalettin Ustun

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

There is a wide variation in the number of CD34+ cells infused for an autologous transplantation. While the minimum number of hematopoietic stem cells for a successful transplantation has been established, there is no definite information on the optimum number or the maximum number of stem cells. It is generally agreed that a minimum dose of 2.5 × 106 CD34+ cells is necessary for successful engraftment. Although engraftment of neutrophils and platelets is achieved at that dose, it is delayed and is also negatively influenced by other factors. Reinfusion of 5.0 × 106 CD34+ cells results in prompt engraftment of all three cell lines and should be the preferred target. At least one study indicated that a very large number of cells (>15 × 106 CD34 + cells) resulted in further improvement in engraftment, decreased packed red blood cell and platelet transfusion, shorter hospitalization, and overall decreased costs. In contrast, a few studies showed that reinfusion of a large number of CD34+ cells causes fever and engraftment syndrome and may result in prolongation of the inpatient stay. Marrow culture assays performed post-transplant have shown decreased hematopoietic reserve as well as changes in the stromal cells. These changes persist for several years after the transplant. Generally, salvage chemotherapy is poorly tolerated post-transplant due to impaired marrow reserve. This hypothesis has not been validated by systematic clinical studies. It is undetermined if larger doses of stem cells improves the marrow reserve.

Original languageEnglish (US)
Pages (from-to)598-606
Number of pages9
JournalStem Cells and Development
Volume13
Issue number6
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Autografts
Cell Count
Bone Marrow
Transplants
Stem Cells
Erythrocyte Transfusion
Platelet Transfusion
Autologous Transplantation
Stromal Cells
Hematopoietic Stem Cells
Inpatients
Hospitalization
Neutrophils
Fever
Blood Platelets
Transplantation
Costs and Cost Analysis
Drug Therapy
Cell Line
Peripheral Blood Stem Cells

ASJC Scopus subject areas

  • Hematology
  • Developmental Biology
  • Cell Biology

Cite this

What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? / Jillella, Anand P.; Ustun, Celalettin.

In: Stem Cells and Development, Vol. 13, No. 6, 01.01.2004, p. 598-606.

Research output: Contribution to journalArticle

@article{83b2ecca606845d4a6897cf9b9893c0c,
title = "What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?",
abstract = "There is a wide variation in the number of CD34+ cells infused for an autologous transplantation. While the minimum number of hematopoietic stem cells for a successful transplantation has been established, there is no definite information on the optimum number or the maximum number of stem cells. It is generally agreed that a minimum dose of 2.5 × 106 CD34+ cells is necessary for successful engraftment. Although engraftment of neutrophils and platelets is achieved at that dose, it is delayed and is also negatively influenced by other factors. Reinfusion of 5.0 × 106 CD34+ cells results in prompt engraftment of all three cell lines and should be the preferred target. At least one study indicated that a very large number of cells (>15 × 106 CD34 + cells) resulted in further improvement in engraftment, decreased packed red blood cell and platelet transfusion, shorter hospitalization, and overall decreased costs. In contrast, a few studies showed that reinfusion of a large number of CD34+ cells causes fever and engraftment syndrome and may result in prolongation of the inpatient stay. Marrow culture assays performed post-transplant have shown decreased hematopoietic reserve as well as changes in the stromal cells. These changes persist for several years after the transplant. Generally, salvage chemotherapy is poorly tolerated post-transplant due to impaired marrow reserve. This hypothesis has not been validated by systematic clinical studies. It is undetermined if larger doses of stem cells improves the marrow reserve.",
author = "Jillella, {Anand P.} and Celalettin Ustun",
year = "2004",
month = "1",
day = "1",
doi = "10.1089/scd.2004.13.598",
language = "English (US)",
volume = "13",
pages = "598--606",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

AU - Jillella, Anand P.

AU - Ustun, Celalettin

PY - 2004/1/1

Y1 - 2004/1/1

N2 - There is a wide variation in the number of CD34+ cells infused for an autologous transplantation. While the minimum number of hematopoietic stem cells for a successful transplantation has been established, there is no definite information on the optimum number or the maximum number of stem cells. It is generally agreed that a minimum dose of 2.5 × 106 CD34+ cells is necessary for successful engraftment. Although engraftment of neutrophils and platelets is achieved at that dose, it is delayed and is also negatively influenced by other factors. Reinfusion of 5.0 × 106 CD34+ cells results in prompt engraftment of all three cell lines and should be the preferred target. At least one study indicated that a very large number of cells (>15 × 106 CD34 + cells) resulted in further improvement in engraftment, decreased packed red blood cell and platelet transfusion, shorter hospitalization, and overall decreased costs. In contrast, a few studies showed that reinfusion of a large number of CD34+ cells causes fever and engraftment syndrome and may result in prolongation of the inpatient stay. Marrow culture assays performed post-transplant have shown decreased hematopoietic reserve as well as changes in the stromal cells. These changes persist for several years after the transplant. Generally, salvage chemotherapy is poorly tolerated post-transplant due to impaired marrow reserve. This hypothesis has not been validated by systematic clinical studies. It is undetermined if larger doses of stem cells improves the marrow reserve.

AB - There is a wide variation in the number of CD34+ cells infused for an autologous transplantation. While the minimum number of hematopoietic stem cells for a successful transplantation has been established, there is no definite information on the optimum number or the maximum number of stem cells. It is generally agreed that a minimum dose of 2.5 × 106 CD34+ cells is necessary for successful engraftment. Although engraftment of neutrophils and platelets is achieved at that dose, it is delayed and is also negatively influenced by other factors. Reinfusion of 5.0 × 106 CD34+ cells results in prompt engraftment of all three cell lines and should be the preferred target. At least one study indicated that a very large number of cells (>15 × 106 CD34 + cells) resulted in further improvement in engraftment, decreased packed red blood cell and platelet transfusion, shorter hospitalization, and overall decreased costs. In contrast, a few studies showed that reinfusion of a large number of CD34+ cells causes fever and engraftment syndrome and may result in prolongation of the inpatient stay. Marrow culture assays performed post-transplant have shown decreased hematopoietic reserve as well as changes in the stromal cells. These changes persist for several years after the transplant. Generally, salvage chemotherapy is poorly tolerated post-transplant due to impaired marrow reserve. This hypothesis has not been validated by systematic clinical studies. It is undetermined if larger doses of stem cells improves the marrow reserve.

UR - http://www.scopus.com/inward/record.url?scp=11144220029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144220029&partnerID=8YFLogxK

U2 - 10.1089/scd.2004.13.598

DO - 10.1089/scd.2004.13.598

M3 - Article

VL - 13

SP - 598

EP - 606

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 6

ER -